Chemotherapy with cisplatin for BRCA1-positive breast cancer patients T.Byrski, S.Narod, J.Lubiński Sopot, 03.09.2010r. INTERNATIONAL HEREDITARY CANCER CENTER POMERANIAN MEDICAL UNIVERSITY, SZCZECIN, POLAND BRCA1 / 2 testing Method: Cost: Time: Myriad sequencing 3 000 USD few weeks IHCC founder mutations 50 Euro 2 3 days
Breast cancers with BRCA1 Treatment Neoadjuvant therapy Type of chemotherapy No of patients Complete Response Partial Response No Response BRCA1 44 AT 15 0 6 9 Other types 29 4 25 0 Total 44 4 31 9 Non-BRCA1 41 AT 12 0 12 0 Other types 29 2 25 2 Total 41 2 37 2 Byrski T et al.: Breast Cancer Res Treat 2007 PRECLINICAL STUDIES BRCA1 breast cancer cell lines - resistance to taxanes - sensitivity to cisplatin Kennedy RD et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 2004 Nov 17;96(22):1659-68.
BRCA1 dependent BC NEOADJUVANT STUDY Current Study Design BRCA1 Mutation Carriers Primary Breast Cancer Cisplatin 75mg/m2 q 3wks IV x 4 cycles S U R G E R Y AC N = 10 60. Primary Endpoint: pcr (in breast and axilla, DCIS permitted)
PILOT STUDY Responses Complete Clinical Response Partial Clinical Response Stable Clinical Disease Progressive Clinical Disease Pathologic Complete Response N (%) (N=10) 9 (90) 1 (10) 0 0 9 (90) Response to treatment RESULTS OF TREATMENT 50 pts 4 x CHTH (CISPL) + CHIR Completed: 26 Aug 2010
Kryteria włączenia do neo-chth (n=50) 23 (+) 13 pcr, 10 PR 27 (-) 21 pcr, 5 PR, 1 SD Response to treatment (n=50) Response No. % Clinical response Complete response 35 70 Partial response 15 30 No change 0 0 Progressive disease 0 0 Pathologic response Complete pathologic response 34 68 Partial reseponse 15 30 Stable disease 1 2 Residual disease in breast after CHTH None 34 68 <2 cm 10 20 2 5 cm 4 8 >5 cm 2 4
Response to treatment (n=50) Response No. % NODAL STATUS PRIOR CHTH N 0 32 64 N 1 13 26 N 2 5 10 N 3 0 0 NODAL STATUS AFTER CHTH N 0 45 90 N 1 3 6 N 2 2 4 N 3 0 0 Breast cancers with BRCA1 Treatment neoadjuvant therapy Cisplatin monotherapy pcr in 34/50 (68%)!!! PR in 15/50 (30%) SD in 1/50 (2%) 10/60 pts on treatment
Breast cancers with BRCA1 Treatment neoadjuvant therapy ATTENTION! Breast cancers with BRCA1 Treatment neoadjuvant therapy 50 pts 7 - second primary BC treated CHTH in the past 4 - treated CHTH before CISPL SURGERY + CHTH (CMF, AT, FAC, AC) 8 pts PR 3 pts - pcr
Breast cancers with BRCA1 Treatment neoadjuvant therapy 39 pts 31/39 = 79,5% pcr CISPLATIN first option of CHTH!
Retrospective analysis neoadjuvant treatment of 141 consecutive BRCA1 mutation carriers with diagnosis of breast cancer < 51 yrs (n=7000) Regimen Number treated Number of pcr % pcr CMF 15 1 7% AC 24 4 17% FAC 28 5 18% AT 24 1 4% Cisplatinum 50 34 68% C: cyclophosphamide M: methotrexate F: 5-flourouracil A: adriamycin T: docetaxel Byrski T et al.: J Clin Oncol. 2010 Jan 20;28(3):375-9 and updated results CHEMOTHERAPY Neo-adjuvant treatment of breast cancer complete pathologic remission > 95% of five year survival! > 95% of five year survival!
Neo-CHTH w BRCA1 dependant breast cancers (literature) Among women who were treated with chemotherapy, the hazard ratio for death among BRCA1 carriers was 0.48 (95% CI, 0.19 to 1.21; p=0.12) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 2 mutations. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA. N Engl J Med. 2007 Jul 12;357(2):115-23. 23. Projekt walidacji badania wieloośrodkowe randomizowane III fazy CISPLATYNA vs AC
PROJEKT WERSJI z dn. 24.07.2010r. Zastosowanie Cisplatyny w monoterapii w porównaniu do schematu AC w leczeniu przedoperacyjnym raka piersi u pacjentek z wykrytą mutacją w genie BRCA1 Główni badacze: prof. dr hab. Jan Lubiński, dr n.med. Tomasz Byrski STEERING COMITTEE: Przewodniczący: prof. dr hab. Maciej Krzakowski Prof. dr hab. Jacek Jassem Prof. dr hab. Cezary Szczylik Prof. dr hab. Tomasz Burzykowski Prof. Steven Narod CEL BADANIA Porównanie skuteczności leczenia przedoperacyjnego cisplatyną w monoterapii z programem AC ocenianej na podstawie częstości uzyskiwanych pcr
Ocena wykonalności badania wykonanie testu BRCA1 u około 13 500 kolejnych nieselekcjonowanych pacjentek z rakiem piersi wykrycie około 400 chorych z konstytucyjną mutacją BRCA1 kwalifikacja 100-120 chorych do CHTH przedoperacyjnej pcr u 70% po CISPL vs 30% po AC p<0.002 prof. T. Burzykowski BRCA1 dependent BC METASTATIC STUDY
Baseline clinical characteristics of the study population (N = 20) Jul 2007 - Jan 2009 Sites of metastases LIVER - 10 LUNG - 9 BONE - 3 OTHER - 11 Line of CHTH of metastatic disease 1-9 2-2 3-8 4-1 Response to treatment Response Number Evidence of progression Months since initiation of treatment,* mean Number deceased Complete 9 3 14.3 0 Partial 7 4 12.9 2 Stable disease 3 2 13.0 2 Progressive 1 1 6.0 1
Response to treatment Overall RR 80% 9 pts CR (45%) 7 pts PR (35%) 1-year survival 93% Toxicity of treatment 1. nausea/vomiting 50% 2. neutropenia 35% 3. anemia 5% 1 pt neutropenia 4 grade GOOD DRUG TOLERANCE!
BRCA1 dependent cancers CANCERS OF OTHER SITES Opis przypadku (dowolna lokalizacja narządowa rak trzustki) 54-letnia pacjentka z rozpoznanym nieoperacyjnym rakiem trzustki (HP: Adenocarcinoma G3) w trakcie rozpoznania stwierdzone mnogie przerzuty do wątroby (największy śr. ok. 36 mm), potwierdzone BACC CA19.9 > 17000 IU/ml Otrzymała a 9 cykli CHTH (DDP 75mg/m 2 ev. 21d.) BADANIE KONTROLNE Zmiana w ogonie trzustki uległa a całkowitej remisji klinicznej (CR) w badaniu TK jamy brzusznej Zmiany metastatyczne w wątrobie uległy y częściowej ciowej regresji (PR), największa 36 mm 17mm CA19.9 ~ 550 IU/ml
CONCLUSIONS 1. Platinum-based chemotherapy is effective in a high proportion of patients with BRCA1-associated breast cancers 2. BRCA1 testing is a critical issue for choice of breast cancer treatment 3. Validating studies needed www.hccpjournal.com
Welcome for collaboration More information: www.hereditarycancer.net e-mail: ihcc@wp.pl phone: +48-91-466-15-42 466-15-42 fax: +48-91-466-15-33 466-15-33 http://hccpjournal.com http://www.read-gene.com http://www.genetyka.com